- Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
- Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
- Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
- Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Arrowhead Pharmaceuticals Inc (HDP1:MUN) closed at 30.59, 14.36% above the 52 week low of 26.75 set on Jun 17, 2022.
26.75Jun 17 202264.76Dec 09 2021
Markit short selling activity
|Market cap||3.60bn USD|
|EPS (TTM)||-1.68 |
Data delayed at least 15 minutes, as of Dec 02 2022 07:01 GMT.